Cargando…
NAFLD and cardiovascular disease
Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726310/ https://www.ncbi.nlm.nih.gov/pubmed/31595238 http://dx.doi.org/10.1016/j.pbj.0000000000000002 |
_version_ | 1783449077706391552 |
---|---|
author | Martins, Elisabete Oliveira, Ana |
author_facet | Martins, Elisabete Oliveira, Ana |
author_sort | Martins, Elisabete |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades. This review focus on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice. |
format | Online Article Text |
id | pubmed-6726310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-67263102019-10-08 NAFLD and cardiovascular disease Martins, Elisabete Oliveira, Ana Porto Biomed J Original Article Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus. Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades. This review focus on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice. 2018-07-18 /pmc/articles/PMC6726310/ /pubmed/31595238 http://dx.doi.org/10.1016/j.pbj.0000000000000002 Text en Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PBJ-Associação Porto Biomedical/Porto Biomedical Society. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Original Article Martins, Elisabete Oliveira, Ana NAFLD and cardiovascular disease |
title | NAFLD and cardiovascular disease |
title_full | NAFLD and cardiovascular disease |
title_fullStr | NAFLD and cardiovascular disease |
title_full_unstemmed | NAFLD and cardiovascular disease |
title_short | NAFLD and cardiovascular disease |
title_sort | nafld and cardiovascular disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726310/ https://www.ncbi.nlm.nih.gov/pubmed/31595238 http://dx.doi.org/10.1016/j.pbj.0000000000000002 |
work_keys_str_mv | AT martinselisabete nafldandcardiovasculardisease AT oliveiraana nafldandcardiovasculardisease |